2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
Ming‐Lung Yu(National Sun Yat-sen University), Wan‐Long Chuang(Kaohsiung Medical University), Chia‐Yen Dai(Kaohsiung Medical University), Tsung‐Hui Hu(National Sun Yat-sen University), Pei‐Jer Chen(National Taiwan University), Chung‐Feng Huang(Kaohsiung Medical University), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Chun‐Jen Liu(National Taiwan University), Chun‐Yen Lin(Chang Gung University), Han‐Chieh Lin(Taipei Veterans General Hospital), Chao‐Hung Hung(Chang Gung University), Chen‐Hua Liu(National Taiwan University Hospital)
Cited by 98
Related Papers
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan
|Gastroenterology|2008|547
Hepatogastroenterology
|Hepatogastroenterology|2012|536